Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes after cladribine tablets in prior CLARITY/CLARITY-EXT and ORACLE MS participants
2019-000069-19Phase 4Completed
- Sponsor
- Merck KGaA
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cladribine in multiple sclerosis (MS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Proportion of study participants using a wheelchair. Started May 2019; status: completed.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-000069-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000069-19.